Endpoints News 11. Apr. 2026 More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more
Endpoints News 10. Apr. 2026 Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push
Endpoints News 10. Apr. 2026 FDA rejects Replimune cancer therapy, saying company didn't resolve trial doubts
Endpoints News 10. Apr. 2026 China biotech’s CRISPR therapy suggests US drugmakers will face competition
Endpoints News 10. Apr. 2026 Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
Endpoints News 10. Apr. 2026 Biotech VCs ramp up checks on new bets after years of focusing on existing portfolios
Endpoints News 10. Apr. 2026 Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Endpoints News 10. Apr. 2026 China-based CAR-T company Oricell raises $40M more as it looks to go public
Endpoints News 9. Apr. 2026 AbbVie suggests new interpretation of 'patient' is necessary in 340B lawsuit
Endpoints News 9. Apr. 2026 Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront